Status:
TERMINATED
Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer
Lead Sponsor:
AstraZeneca
Conditions:
Neoplasms
Breast Neoplasms
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
The main purpose of this study is to compare progression free survival in patients treated with AZD8931 given in combination with anastrozole versus anastrozole alone. The secondary objective is to in...
Eligibility Criteria
Inclusion
- Patients that have locally advanced or metastatic breast cancer. Lesions should not be amenable to surgery or radiation of curative intent
- Hormone therapy-naive
- Estimated life expectancy of more than 12 weeks
Exclusion
- Last dose of prior anti-cancer therapy received within 14 days (or longer if required)
- Any eye injury or corneal surgery within 3 months prior to receiving first dose of study drug.
- Currently receiving (and unwilling to discontinue) oestrogen replacement therapy. (last dose \<7 days prior to randomisation)
Key Trial Info
Start Date :
June 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2013
Estimated Enrollment :
482 Patients enrolled
Trial Details
Trial ID
NCT01151215
Start Date
June 1 2010
End Date
January 1 2013
Last Update
July 25 2014
Active Locations (60)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Lake Success, New York, United States
2
Research Site
Belo Horizonte, Brazil
3
Research Site
Goiânia, Brazil
4
Research Site
Ijuí, Brazil